Azerion Publication Date Of Q3 2024 Results Set For 19 November 2024
Date
10/17/2024 11:09:20 PM
(MENAFN- GlobeNewsWire - Nasdaq) Amsterdam, 18 October 2024 - Azerion, one of Europe's largest digital advertising and entertainment media platforms, announces the adjustment of its upcoming Q3 interim unaudited financial reporting date to 19 November 2024, ten days earlier than the previously scheduled 28 November 2024. Over the past year, integration and consolidation efforts have helped Azerion mature as a publicly listed company, resulting in improved reporting efficiencies. These enhancements support Azerion's growth and commitment to timely reporting while enabling it to capture opportunities faster and expand its market share. Future reporting dates:
| Q3 2024 | Q4 and FY 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
| 19 November 2024 | 27 February 2025 | 28 May 2025 | 28 August 2025 | 18 November 2025 |
About Azerion
Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe's largest digital advertising and entertainment media platforms. Azerion brings global scaled audiences to advertisers in an easy and cost-effective way, delivered through our proprietary technology, in a safe, engaging, and high quality environment, utilizing our strategic portfolio of owned and operated content with entertainment and other digital publishing partners.
Having its roots in Europe and with its headquarters in Amsterdam, Azerion has commercial teams based in over 22 cities around the world to closely support our clients and partners to find and execute creative ways to make a real impact through advertising.
For more information visit:
Contact
Investor Relations: ...
Media: ...
MENAFN17102024004107003653ID1108793561
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.